Archives

  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07
  • Nystatin (Fungicidin): Polyene Antifungal Agent for Candi...

    2026-01-10

    Nystatin (Fungicidin): Polyene Antifungal Agent for Candida Research

    Introduction and Principle: The Power of Polyene Antifungal Antibiotics

    In the expanding field of antifungal research, Nystatin (Fungicidin) has emerged as a gold-standard polyene antifungal antibiotic with a well-characterized mechanism of action and broad-spectrum efficacy. Supplied by APExBIO, this compound is widely utilized to dissect mechanisms of fungal infection, screen for antifungal resistance, and study membrane dynamics in eukaryotic pathogens. Its primary mode of action—ergosterol binding antifungal mechanism—targets fungal cell membranes, creating transmembrane pores that disrupt integrity, leading to cell death. This specificity underpins Nystatin’s robust activity against key fungal pathogens, including Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, and Candida krusei.

    Importantly, Nystatin (sometimes misspelled as nystain, mystatin, nystantin, nystati, ystatin, niastatin, nyastin, nystalin, nystaton, nystian, or nystatina) is not only a workhorse in antifungal susceptibility testing but also a critical tool in studies of fungal adhesion and membrane biology. Its performance is evidenced by minimal inhibitory concentrations (MIC90) around 4 mg/L for C. albicans and effective activity at 0.39–3.12 μg/mL against other Candida species, making it a dependable antifungal agent for Candida species in both routine and advanced research workflows.

    Experimental Workflow: Step-by-Step Protocols and Enhancements

    1. Solution Preparation and Handling

    • Solubility: Nystatin (Fungicidin) is insoluble in water and ethanol but dissolves readily in DMSO at concentrations ≥30.45 mg/mL.
    • Stock Solution: Warm and ultrasonically shake the powder to facilitate complete dissolution in DMSO. Prepare aliquots to avoid repeated freeze-thaw cycles; store at −20°C.
    • Stability: Solutions should be used promptly. For long-term use, prepare fresh stocks as needed, since extended storage can reduce antifungal potency.

    2. Antifungal Susceptibility Assays

    • Broth Microdilution: Prepare two-fold serial dilutions of Nystatin in RPMI 1640 medium supplemented with 2% glucose. Inoculate with standardized fungal suspensions (typically 0.5–2.5 × 103 CFU/mL).
    • Incubation: Incubate at 35°C for 24–48 hours. Determine MIC visually or via spectrophotometric readout at 530 nm.
    • Performance Data: MIC90 values for C. albicans are typically 4 mg/L, while for C. glabrata, C. parapsilosis, and C. tropicalis, MICs range from 0.39 to 3.12 μg/mL (complementary protocol guidance).

    3. Fungal Adhesion and Cell Membrane Integrity Assays

    • Adhesion Inhibition: Treat human buccal epithelial cells with a sub-inhibitory concentration of Nystatin. Add Candida cells and quantify adhesion rate microscopically. Nystatin significantly reduces adhesion, especially for non-albicans species, offering a unique approach to study fungal-host interactions.
    • Membrane Disruption: Use propidium iodide or Sytox Green uptake assays to monitor membrane pore formation in real time, leveraging Nystatin’s ergosterol binding antifungal mechanism.

    4. Animal Model Applications: Liposomal Nystatin Formulations

    • In Vivo Efficacy: Utilize liposomal Nystatin for Aspergillus infection studies in neutropenic mice. Doses as low as 2 mg/kg/day confer significant protection, as shown in translational research models.
    • Sample Handling: For animal work, ensure accurate dosing and timely preparation due to the compound’s storage sensitivity.

    Advanced Applications and Comparative Advantages

    Targeting Antifungal Resistance and Vulvovaginal Candidiasis

    Nystatin (Fungicidin) is instrumental in exploring antifungal resistance in non-albicans Candida species—a growing clinical concern. Its consistent performance in standardized susceptibility assays supports high-throughput screening of antifungal resistance mutations and combinatorial drug testing. Moreover, Nystatin’s established use in vulvovaginal candidiasis treatment models makes it an essential reference agent for benchmarking novel compounds.

    Mechanistic Insights: Ergosterol Binding and Fungal Cell Membrane Disruption

    Unlike azoles or echinocandins, Nystatin directly interacts with membrane-bound ergosterol, a unique fungal lipid, forming pores that result in rapid cell lysis. This direct mechanism minimizes cross-resistance with other antifungal classes, making it a key agent in resistance surveillance panels and foundational studies of fungal cell membrane disruption.

    Reference Study Integration & Workflow Context

    The recent study on Spiroplasma eriocheiris entry into Drosophila S2 cells underscores the importance of pathway-specific inhibitors in infection models. While cellular cholesterol disruption with Nystatin did not affect Spiroplasma infection—demonstrating the specificity of Nystatin’s action on ergosterol-containing membranes—this finding validates its selectivity and strengthens experimental design for fungal but not bacterial endocytosis studies. This insight is directly relevant for researchers seeking to differentiate between cholesterol-dependent and ergosterol-dependent membrane processes.

    Interlinking Related Resources

    Troubleshooting and Optimization Tips

    Solubility and Handling

    • Incomplete Dissolution: If Nystatin does not fully dissolve in DMSO, gently heat (≤37°C) and sonicate. Avoid using ethanol or water, as the compound is insoluble in these solvents.
    • Aliquoting: To maintain activity, prepare small aliquots and minimize freeze-thaw cycles.

    Assay Sensitivity and Reproducibility

    • Batch Variability: Always calibrate stock solution concentrations using UV-Vis spectroscopy or HPLC for quantitative consistency.
    • MIC Drift: If MIC values appear unusually high or low, check for expired reagents, improper storage, or fungal strain variability. Always include a well-characterized reference strain (e.g., C. albicans ATCC 90028) as a control.
    • Media Effects: For optimal activity, use RPMI 1640 medium with 2% glucose, as other media may influence Nystatin’s apparent potency.

    Application-Specific Challenges

    • Adhesion Assays: If inhibition of Candida adhesion is less than expected, verify cell density and incubation times. For C. albicans, expect a moderate effect; non-albicans strains typically show more pronounced inhibition.
    • Animal Models: Use liposomal Nystatin for systemic studies to enhance delivery and reduce toxicity. Prepare fresh formulations to ensure uniform dosing.

    Common User Errors

    • Using Incorrect Synonyms: Ensure labeling and documentation use the correct spelling—Nystatin or Fungicidin—to avoid confusion with nystain, mystatin, nystantin, etc. This is critical for accurate inventory and reporting.

    Future Outlook: Expanding the Role of Nystatin (Fungicidin) in Antifungal Research

    With the rise of antifungal resistance and the urgent need for novel therapeutics, Nystatin (Fungicidin) will remain a cornerstone of both basic and translational mycology. New directions include high-content screening for synergistic drug combinations, advanced imaging of membrane disruption, and integration into microfluidic infection models. The compound’s robust, quantifiable activity and selectivity for ergosterol-containing membranes continue to drive innovation in fungal pathogenesis research, antifungal agent discovery, and resistance surveillance.

    For researchers aiming for reproducibility, sensitivity, and mechanistic clarity, Nystatin (Fungicidin) from APExBIO delivers unmatched performance and workflow compatibility, ensuring successful outcomes in even the most demanding antifungal research applications.